UK Technical Documentation Requirements for Medical Devices

1. Key takeaways

The United Kingdom does not have a standalone regulation that prescribes the format of technical documentation for medical devices. Instead, the technical documentation requirements are distributed across the conformity assessment provisions of UK MDR 2002 and the annexes those provisions incorporate, as amended by Schedule 2A. For manufacturers, this means that a technical file or design dossier assembled for the EU can serve as the underlying source material, but it cannot be reused as-is. Three localisation tasks must be completed: the relevant essential requirements must be mapped and replaced clause by clause, the EU Declaration of Conformity must be replaced by a UK Declaration of Conformity, and the language and UKRP information must be adapted so that the documentation is complete and retrievable within Great Britain. Skipping any one of these steps is the most common reason an EU-style dossier fails to support a UK registration or an MHRA documentation request. Each of the three tasks is examined in the sections below, together with the legal provisions that drive them and the practical structures that make them manageable on an ongoing basis. Treat this article as a checklist-driven overview: it identifies what must exist, where each obligation comes from and who holds which document, without restating every procedural detail of the individual conformity assessment routes.

2. Legal basis

• UK MDR 2002 (SI 2002/618, as amended): reg 8 and reg 9 (the relevant essential requirements and the assessment of conformity with them); reg 13/27/40 (the affixing procedures for general devices, active implantable devices and IVDs respectively); reg 17/30/41 (the conformity assessment procedures for each of the three device families); reg 15/28 (the procedures for custom-made devices); and Schedule 2A (the amendments made to the annexes of Directives 90/385, 93/42 and 98/79 as they have effect in UK law).
• SI 2024/1368 (in force 16 June 2025): reg 3 amends relevant definitions in reg 2(1); Part 4A requires that post-market surveillance (PMS) data be fed back into the technical documentation.
• Official guidance: GOV.UK, Regulating medical devices in the UK, which states that the UKRP must keep copies of the technical documentation, copies of the Declaration of Conformity and copies of the relevant certificates, all available for inspection by the MHRA on request.

3. Expert insights

Insight one: the UKRP is the custodian of the technical documentation. The official guidance sets out the UKRP’s legal duties in this area, and they are worth reading carefully. The UKRP must ensure that the Declaration of Conformity and the technical documentation have been drawn up, and it must keep copies of the technical documentation, copies of the Declaration of Conformity and copies of the relevant certificates, including any amendments and supplements, available for inspection when the MHRA requests them. The practical consequence is significant: technical documentation is not something that can simply remain filed at the manufacturer’s headquarters outside the UK. It must be retrievable within Great Britain, and the agreement with the UKRP should reflect that reality rather than treat document custody as an afterthought. Manufacturers should also note that the duty covers certificates together with their amendments and supplements, so every revised certificate version should reach the UKRP’s copy set as part of routine document control.

Insight two: PMS data must flow back into the technical documentation. The PMS system established under Part 4A requires post-market data to be used to update the technical documentation, including the risk analysis and the clinical evaluation. This changes the character of the technical file. A dossier that was written once for the purpose of obtaining a certificate and then archived, never to be touched again, is now a system defect rather than a convenience. Manufacturers should treat the technical documentation as a living record whose sections on risk, clinical evidence and essential requirements move in step with the complaints, vigilance and literature monitoring data that the PMS system generates.

Insight three: the MHRA can request the technical documentation directly. The official guidance is explicit that, as part of its verification and review of registration data, the MHRA may request further technical documentation to demonstrate that a product conforms with the requirements of the medical devices regulations. Registration is therefore not the end of regulatory scrutiny; it is the beginning of it. A registration that cannot be backed by a coherent, current and retrievable technical file creates exposure precisely when the manufacturer least wants it, namely during an MHRA review that operates on its own timetable. In GRZAN’s experience, the requests rarely arrive with long lead times, so the documentation architecture described in section 4 is designed around speed of retrieval as much as around technical completeness.

4. Practical recommendations

GRZAN recommends organising the documentation around a single set of source data plus two mapping tables. The source data, meaning the test reports, the risk documentation and the clinical evidence, remain common to both jurisdictions. The mapping tables then point from the source data to the UK relevant essential requirements on one side and to the EU general safety and performance requirements on the other. This structure avoids maintaining two divergent dossiers that drift apart over time. In parallel, the manufacturer and the UKRP should agree in writing on the custody arrangements, the retrieval timeline and the notification mechanism for updates to the technical documentation. GRZAN suggests recording these arrangements in an annex to the UKRP authorisation letter, so that the operational commitment is documented in the same instrument that creates the appointment itself and can be enforced if personnel or organisations change. For manufacturers operating both routes in parallel, GRZAN suggests keeping the two mapping tables in one workbook, so that a change to shared source data updates both destinations under a single review.

5. Verification checklist

• □ The clause-by-clause mapping to the UK relevant essential requirements has been completed
• □ A UK Declaration of Conformity has been issued, rather than an EU DoC
• □ The UKRP holds copies of the technical documentation and the DoC
• □ A mechanism exists for PMS data to be fed back into the technical documentation
• □ A response timeline has been agreed for MHRA documentation requests

Regulatory information verified as of 29 October 2026.

GRZAN supports manufacturers entering the UK market with the preparation and maintenance of registration documentation and conformity documentation. Our services for the UK market include:

• UK Responsible Person (UKRP) appointment and authorisation letter support
• Full MHRA registration (DORS) filing and account lifecycle management
• Device classification, GMDN code selection and annual registration fee calculation
• Great Britain and Northern Ireland dual-pathway design and UK(NI) solutions
• Post-market surveillance (PMS) system setup, PMSR/PSUR preparation and vigilance reporting
• Serious incident and field safety corrective action (FSCA) emergency response
• UK regulatory change monitoring and compliance gap assessment

For tailored support with UK technical documentation, registration and conformity documentation, contact GRZAN at info@grzanglobal.com.